GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commenc...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focus...
ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, announced that it has received a P...
a clinical-stage biotechnology company developing novel immunotherapies, announced the company will deliver poster presentations at the Society for I...
Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced that the United States (U.S.) Food and D...
bluebird bio, Inc. (Nasdaq: BLUE) announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a detailed analysis of the positive Phase III INAVO120 results, evaluat...
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic c...
GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...
JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...
RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics...
© 2024 Biopharma Boardroom. All Rights Reserved.
